Amgen [AMGN] vs Pfizer [PFE] Detailed Stock Comparison
Amgen
NASDAQ
Loading...
Pfizer
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Amgen wins in 9 metrics, Pfizer wins in 11 metrics, with 0 ties. Pfizer appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amgen | Pfizer | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 22.33 | 12.55 | Pfizer |
| Price-to-Book Ratio | 21.63 | 1.53 | Pfizer |
| Debt-to-Equity Ratio | 756.65 | 69.70 | Pfizer |
| PEG Ratio | 0.24 | 0.00 | Pfizer |
| EV/EBITDA | 12.94 | 7.54 | Pfizer |
| Profit Margin (TTM) | 18.96% | 16.84% | Amgen |
| Operating Margin (TTM) | 32.73% | 28.68% | Amgen |
| EBITDA Margin (TTM) | 32.73% | 28.68% | Amgen |
| Return on Equity | 99.14% | 12.17% | Amgen |
| Return on Assets (TTM) | 7.51% | 5.25% | Amgen |
| Free Cash Flow (TTM) | $10.39B | $9.84B | Amgen |
| Dividend Yield | 4.09% | 5.32% | Pfizer |
| 1-Year Return | -6.96% | -5.25% | Pfizer |
| Price-to-Sales Ratio (TTM) | 4.60 | 2.12 | Pfizer |
| Enterprise Value | $208.88B | $184.71B | Amgen |
| EV/Revenue Ratio | 5.98 | 2.89 | Pfizer |
| Gross Profit Margin (TTM) | 67.20% | 74.22% | Pfizer |
| Revenue per Share (TTM) | $65 | $11 | Amgen |
| Earnings per Share (Diluted) | $13.37 | $1.90 | Amgen |
| Beta (Stock Volatility) | 0.48 | 0.46 | Pfizer |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Amgen vs Pfizer Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amgen | -0.37% | 9.67% | 3.65% | 0.19% | -2.72% | 14.70% |
| Pfizer | -0.48% | 14.75% | 8.41% | 6.95% | 9.64% | 1.77% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amgen | -6.96% | 29.85% | 25.64% | 98.81% | 427.40% | 286.13% |
| Pfizer | -5.25% | -36.01% | -22.43% | -14.14% | 63.43% | 17.03% |
News Based Sentiment: Amgen vs Pfizer
Amgen
News based Sentiment: POSITIVE
Amgen experienced a highly positive month, driven by strong Q2 earnings that exceeded expectations, significant manufacturing investments, positive clinical trial results for Repatha leading to expanded FDA approval, and a subsequent increase in stock price. These factors collectively strengthen the investment case for Amgen.
Pfizer
News based Sentiment: MIXED
Pfizer had a month of both positive developments – a major acquisition and strong Q2 earnings – and concerning headwinds, including looming patent expirations and increasing debt. The Metsera deal is a significant strategic move, but the overall investment story remains complex and requires careful monitoring.
Performance & Financial Health Analysis: Amgen vs Pfizer
| Metric | AMGN | PFE |
|---|---|---|
| Market Information | ||
| Market Cap | $160.11B | $147.88B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 3,455,190 | 50,010,390 |
| 90 Day Avg. Volume | 2,483,153 | 43,344,040 |
| Last Close | $297.40 | $27.08 |
| 52 Week Range | $253.30 - $335.88 | $20.92 - $30.43 |
| % from 52W High | -11.46% | -11.01% |
| All-Time High | $346.85 (Jul 22, 2024) | $61.71 (Dec 20, 2021) |
| % from All-Time High | -14.26% | -56.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.10% |
| Quarterly Earnings Growth | 0.92% | 69.98% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.17% |
| Operating Margin (TTM) | 0.33% | 0.29% |
| Return on Equity (TTM) | 0.99% | 0.12% |
| Debt to Equity (MRQ) | 756.65 | 69.70 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.80 | $15.60 |
| Cash per Share (MRQ) | $14.91 | $2.33 |
| Operating Cash Flow (TTM) | $12.01B | $15.19B |
| Levered Free Cash Flow (TTM) | $10.42B | $16.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | 4.09% | 5.32% |
| Last 12-Month Dividend | $11.64 | $1.27 |
Valuation & Enterprise Metrics Analysis: Amgen vs Pfizer
| Metric | AMGN | PFE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 22.33 | 12.55 |
| Forward P/E | 14.44 | 8.14 |
| PEG Ratio | 0.24 | 0.00 |
| Price to Sales (TTM) | 4.60 | 2.12 |
| Price to Book (MRQ) | 21.63 | 1.53 |
| Market Capitalization | ||
| Market Capitalization | $160.11B | $147.88B |
| Enterprise Value | $208.88B | $184.71B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.98 | 2.89 |
| Enterprise to EBITDA | 12.94 | 7.54 |
| Risk & Other Metrics | ||
| Beta | 0.48 | 0.46 |
| Book Value per Share (MRQ) | $13.80 | $15.60 |
Financial Statements Comparison: Amgen vs Pfizer
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMGN | PFE |
|---|---|---|
| Revenue/Sales | $8.15B | $14.65B |
| Cost of Goods Sold | $2.97B | $3.78B |
| Gross Profit | $5.18B | $10.88B |
| Research & Development | $1.49B | $2.48B |
| Operating Income (EBIT) | $1.18B | $3.77B |
| EBITDA | $4.08B | $5.75B |
| Pre-Tax Income | $1.97B | $3.04B |
| Income Tax | $243.00M | $141.00M |
| Net Income (Profit) | $1.73B | $2.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMGN | PFE |
|---|---|---|
| Cash & Equivalents | $8.81B | $1.43B |
| Total Current Assets | $26.93B | $45.86B |
| Total Current Liabilities | $23.01B | $36.45B |
| Long-Term Debt | $54.01B | $56.82B |
| Total Shareholders Equity | $6.21B | $90.64B |
| Retained Earnings | $-27.14B | $119.59B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMGN | PFE |
|---|---|---|
| Operating Cash Flow | $1.71B | $3.91B |
| Capital Expenditures | $-411.00M | $-564.00M |
| Free Cash Flow | $980.00M | $1.77B |
| Debt Repayment | $-2.50B | $-2.43B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AMGN | PFE |
|---|---|---|
| Shares Short | 13.20M | 112.93M |
| Short Ratio | 6.63 | 2.85 |
| Short % of Float | 0.02% | 0.02% |
| Average Daily Volume (10 Day) | 3,455,190 | 50,010,390 |
| Average Daily Volume (90 Day) | 2,483,153 | 43,344,040 |
| Shares Outstanding | 537.00M | 5.67B |
| Float Shares | 536.99M | 5.68B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.84% | 0.67% |
Dividend Analysis & Yield Comparison: Amgen vs Pfizer
| Metric | AMGN | PFE |
|---|---|---|
| Last 12-Month Dividend | $11.64 | $1.27 |
| Last 12-Month Dividend Yield | 4.09% | 5.32% |
| 3-Year Avg Annual Dividend | $9.51 | $1.52 |
| 3-Year Avg Dividend Yield | 0.80% | 1.27% |
| 3-Year Total Dividends | $28.54 | $4.55 |
| Ex-Dividend Date | Aug 22, 2025 | Jan 24, 2025 |